Hansoh Pharmaceutical Group CO Ltd (HNSPF)

$4.04 +0.49 (13.86%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 1,000
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 86 40 0828 5227
Address:
287 Xiangke Road, Pudong New District, Shanghai, China
Biotekman
Biotekman Apr. 11 at 8:06 PM
$HNSPF Dear all, could you confirm that ibrexafungerp (Brexafemme), was just approved in China?
1 · Reply
Quantumup
Quantumup Dec. 18 at 1:34 PM
BMO Capital Questions Whether $MRK (Merck) would have been better served going after a company in later-stage development, given the strength of their balance sheet and the proximity of the Keytruda LOE. $HNSPF $VKTX $GPCR $TERN LLY NVO BMO Capital reiterated $MRK Outperform; $136, says 'Merck Enters Obesity w/ the License of Hansoh's Small Molecule GLP-1 HS-10535:' "Solving for the Keytruda LOE? Merck enters the obesity race with plans to in-license Hansoh Pharma's preclinical oral small molecule GLP-1RA HS-10535 for an upfront of $112M with a potential $1.9B in milestone payments. Today's transaction likely viewed as positive by the investment community, but we question whether Merck would have been better served going after company in later-stage development, given the strength of their balance sheet and the proximity of the Keytruda LOE."
0 · Reply
DonCorleone77
DonCorleone77 Aug. 20 at 10:47 AM
$GSK $HNSPF GSK receives U.S. FDA Breakthrough Therapy Design for GSK5764227 GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation for GSK5764227, GSK'227, the Company's investigational B7-H3-targeted antibody drug conjugate, ADC, being evaluated for the treatment of patients with extensive-stage small-cell lung cancer, ES-SCLC, with disease progression on or after platinum-based chemotherapy. The Breakthrough Therapy Designation aims to expedite the development and review of drugs with the potential to treat a serious condition and where preliminary clinical evidence may indicate substantial improvement over currently available therapy. Earlier this year, GSK acquired exclusive worldwide rights from Hansoh Pharma (HNSPF) to progress clinical development and commercialisation of GSK'227. FDA's Breakthrough Therapy Designation is supported by data from the ongoing ARTEMIS-001 Phase 1 open-label and preliminary anti-tumour activity in locally advanced or metastatic solid tumours.
0 · Reply
fda_tracker
fda_tracker Feb. 13 at 2:05 PM
$HNSPF Phase 2 trial w/est Feb completion date NCT06118008: https://www.clinicaltrials.gov/study/NCT06118008 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
Latest News on HNSPF
No data available.
Biotekman
Biotekman Apr. 11 at 8:06 PM
$HNSPF Dear all, could you confirm that ibrexafungerp (Brexafemme), was just approved in China?
1 · Reply
Quantumup
Quantumup Dec. 18 at 1:34 PM
BMO Capital Questions Whether $MRK (Merck) would have been better served going after a company in later-stage development, given the strength of their balance sheet and the proximity of the Keytruda LOE. $HNSPF $VKTX $GPCR $TERN LLY NVO BMO Capital reiterated $MRK Outperform; $136, says 'Merck Enters Obesity w/ the License of Hansoh's Small Molecule GLP-1 HS-10535:' "Solving for the Keytruda LOE? Merck enters the obesity race with plans to in-license Hansoh Pharma's preclinical oral small molecule GLP-1RA HS-10535 for an upfront of $112M with a potential $1.9B in milestone payments. Today's transaction likely viewed as positive by the investment community, but we question whether Merck would have been better served going after company in later-stage development, given the strength of their balance sheet and the proximity of the Keytruda LOE."
0 · Reply
DonCorleone77
DonCorleone77 Aug. 20 at 10:47 AM
$GSK $HNSPF GSK receives U.S. FDA Breakthrough Therapy Design for GSK5764227 GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation for GSK5764227, GSK'227, the Company's investigational B7-H3-targeted antibody drug conjugate, ADC, being evaluated for the treatment of patients with extensive-stage small-cell lung cancer, ES-SCLC, with disease progression on or after platinum-based chemotherapy. The Breakthrough Therapy Designation aims to expedite the development and review of drugs with the potential to treat a serious condition and where preliminary clinical evidence may indicate substantial improvement over currently available therapy. Earlier this year, GSK acquired exclusive worldwide rights from Hansoh Pharma (HNSPF) to progress clinical development and commercialisation of GSK'227. FDA's Breakthrough Therapy Designation is supported by data from the ongoing ARTEMIS-001 Phase 1 open-label and preliminary anti-tumour activity in locally advanced or metastatic solid tumours.
0 · Reply
fda_tracker
fda_tracker Feb. 13 at 2:05 PM
$HNSPF Phase 2 trial w/est Feb completion date NCT06118008: https://www.clinicaltrials.gov/study/NCT06118008 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply